DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claim 13 has been cancelled. Claims 1, 4, 9, 10, 12, and 14 have undergone amendments. Claim 15 is newly added. Thus, Claims 1, 4, 5, 9, 10, 12, 14, and 15, submitted on 26 August 2026, represent all claims currently under consideration.
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
Response to Arguments
The objection to the specification is withdrawn. Applicant has provided a new specification which has the increased line spacing.
The 35 U.S.C. § 101 rejection of Claims 4, 9, 10, 12, and 13 is withdrawn. Applicant has amended the claims to recite a method for treating non-melanoma skin cancer.
The 35 U.S.C. § 112(a) rejection of Claims 1, 5, and 14 is withdrawn. Applicant has amended the claim to recite the treatment of non-melanoma skin cancer, which is enabled by the specification.
The 35 U.S.C. § 102(a)(1) rejection of Claims 4 and 13 over Sherman is withdrawn. Applicant has amended the claims to recite a method of treating non-melanoma skin cancer, which is not taught by Sherman.
The 35 U.S.C. § 103 rejection of Claims 4, 9, 10, 12, and 13 over Sherman in view of Uwitonze and Xv is withdrawn. Sherman does not disclose the treatment of a non-melanoma skin cancer.
The 35 U.S.C. § 103 rejection of Claims 1, 4, 5, 9, 10, 12, and 14 over Albert in view of Uhmann, Trump, Uwitonze, and Xv is maintained. Applicant argues that the combined references do not render the claims obvious as the references do not provide an enabling disclosure for treating non-melanoma skin cancer, and there is no reasonable expectation of success for modifying Albert to treat non-melanoma skin cancers according to the teachings of Uhmann, Turmp, Uwitonze, and/or Xv. The Examiner respectfully disagrees. Albert specifically teaches the nexus between the vitamin D receptor in a basal cell carcinoma cell line (which is a form of non-melanoma skin cancer). Albert discusses that vitamin D3, as well as its active metabolite calcitriol exert an antitumor effects, and are ascribed to the inhibition of Hh signaling. They provide more evidence that in vitamin D receptor deficient mice, calcitriol suppresses this signaling pathway in a vitamin D receptor dependent fashion. Further, Albert states that calcitriol has been shown to inhibit the proliferation of keratinocytes, and that vitamin D receptor deficiency increases the susceptibility to develop non-melanoma skin cancers. Albert then further references studies which demonstrates that calcitriol, cholecalciferol, and calcidiol inhibit hedgehog signaling, which restrains the growth of non-melanoma skin cancers, with Albert explicitly stating that these finds have important implications for basal cell carcinoma therapy, and represents a new option for the treatment of basal cell carcinomas, providing both a motivation and reasonable expectation of success in applying vitamin D3 and its metabolites for the treatment of these conditions. Uhmann further expands on these signaling pathways and their involvement in the development of basal cell carcinoma, further providing a motivation and reasonable expectation of success for the treatment of non-melanoma skin cancers.
Claim Rejections - 35 USC § 103- REJECTIONS MAINTAINED
The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
Claims 1, 4, 5, 9, 10, 12, 14 and 15 are rejected under 35 U.S.C. 103 as being unpatentable over Albert (Chapter 18 of Sunlight, Vitamin D and Skin Cancer, Second Edition, 2014, Interaction of Hedgehog and Vitamin D Signaling Pathways in Basal Cell Carcinomas) in view of Uhmann (Molecular Medicine in Practice, Volume 10, Issue 11, 1 November 2011), Trump (Cancer J. 2010; 16(1): 1-9), Uwitonze (Journal of the American Osteopathic Association, March 2018, Vol. 118, No. 3) and Xv (Oncology Letters, 15, 8926-8934, 2018).
Determining the Scope and Contents of the Prior Art:
Albert provides an overview of vitamin D in basal cell carcinoma (a form of non-melanoma skin cancer). Most basal cell carcinomas are caused by mutational inactivation of the tumor suppressor Patched (PTCH), which results in activation of Smoothened (SMO) and of the Hedgehog (HH) signaling pathways. Recent studies indicate that BCC progression involves a crosstalk between Hh signaling, vitamin D derivatives and the vitamin D receptor (VDR) signaling pathway. This has been demonstrated in BCC-bearing Ptch mutant mice and BCC cell lines, in which both vitamin D3 and its active metabolite calcitriol exert antitumor effects. The antitumor effects are mainly ascribed to an inhibition of Hh signaling. As evident from studies in Vdr deficient mice, calcitriol may also repress the activity of Hh signaling in a Vdr-dependent fashion thereby establishing an additional inhibitory feedback on Hh signaling activity (Abstract). Vitamin D3 is synthesized in keratinocytes, or comes from dietary sources. It is then transported in the blood to the liver, where it is hydroxylated to form calcidiol, which is then transported to the kidney and is hydroxylated to the hormonally active calcitriol, which binds to and activates the VDR in many tissues. The amount of calcidiol and calcitriol is limited by the enzyme 24-hydroxylase. Therefore, 24-hydroxylase limits the amount of calcitriol by both accelerating catabolism of calcitriol and by decreasing the amount of calcidiol available for calcitriol synthesis. The concentrations of calcitriol are regulated by several feedback loops. Furthermore, calcitriol (through binding of the VDR) represses the transcription of Cyp27b1, which results in inhibition of its own production. Calcitriol enhances VDR expression at the mRNA and protein levels, due to an increased transcription of the VDR gene and/or an increased receptor protein lifetime. In the skin, calcitriol has been shown to inhibit proliferation of keratinocytes by changing the expression of cell cycle regulators, and to induce differentiation markers. Data has shown that Vdr deficiency increases the susceptibility to BCCs. (Vitamin D Signaling in BCCs, Page 332-333). Anti-Hh effects of Vitamin D3 and calcitriol were also reported by Banerjee and colleagues, who conducted a structure-activity relationship survey to elucidate the role of Vitamin D3 derivatives in Hh pathway inhibition. The experiments showed that calcitriol as well as vitamin D3 and calcidiol inhibited Hh signaling, and that calcitriol was more potent than vitamin D3 (Page 337, first paragraph). Both vitamin D3 and its hormonally active form calcitriol inhibit Hh signaling probably by a direct interaction with Smo, which is followed by restrained BCC growth. Calcitriol activates Vdr signaling in BCC cells, further intensifying anti-Hh activity due to suppression of protein levels of several Hh pathway members. These findings have important implications for BCC therapy. Because vitamin D has relatively moderate side effects and is tolerated quite well, it could be a new option for treatment of BCCs (Conclusion).
Uhmann studied the activation of the Hedgehog (Hh)-signaling pathway due to deficiency in the Hh receptor Patched1 (Ptch) is the pivotal defect leading to formation of basal cell carcinoma (BCC). Recent reports provided evidence of Ptch-dependent secretion of vitamin D3-related compounds, which functions as endogenous inhibitor of Hh signaling by repressing the activity of the signal transduction partner of Ptch, Smoothened (Smo). This suggests that Ptch-deficient tumor cells are devoid of this substance, which in turn results in activation of Hh-signaling. The authors show that application of the physiologically active form of vitamin D3, calcitriol, inhibits proliferation and growth of BCC of Ptch mutant mice in vitro and in vivo. This is accompanied by the activation of the vitamin D receptor and induction of BCC differentiation. Calcitriol inhibits Hh signaling at the level of Smo in a Vdr-independent manner. The concomitant antiproliferative effects on BCC growth are stronger than those of the Hh-specific inhibitor cyclopamine. Taken together, the results show that exogenous supply of calcitriol controls the activity of 2 independent pathways, Hh and Vdr signaling, which are relevant to tumorigenesis and tumor treatment. The data suggest that calcitriol could be a therapeutic option in the treatment of BCC, the most common tumor in humans (Abstract).
Trump provides a review of vitamin D in the treatment of cancer. Many preclinical studies indicate that exposing cancer cells- as well as vascular endothelial cells derived from tumors- to high concentrations of active metabolites of vitamin D halts progression through cell cycle, induces apoptosis, and will slow or stop the growth of tumors in vivo. Vitamin D analogues initiate signaling through a number of important pathways, but the pathways essential to the antitumor activities of vitamin D are unclear. Clinical studies of vitamin D as an anti-tumor agent have been hampered by lack of a suitable pharmaceutical preparation for clinical study. All commercially available formulations are inadequate because of the necessity to administer large numbers of caplets and the poor bioavailability of calcitriol (the most carefully studied analogue) at these high doses. Preclinical data suggests that very high exposures to calcitriol are necessary for the antitumor effects. Clinical data indicates that very high doses of calcitriol can be given safely. The maximum tolerated dose of calcitriol is unclear (Abstract).
Uwitonze teaches the role of magnesium in ensuring the biological activity of vitamin D. Magnesium assists in the activation of vitamin D. All of the enzymes that metabolize vitamin D require magnesium, which acts as a cofactor in the enzymatic reactions in the liver and kidneys. It is therefore essential to ensure that the recommended amount of magnesium is consumed to obtain the optimal benefits of vitamin D (Abstract). Vitamin D, either D3 or D2, does not have significant biological activity. It needs to be processed further in the liver and kidneys to generate its biologically active forms. The enzymatic activity of both the hepatic and renal enzymes are magnesium dependent. The activity of vitamin D-binding protein is also a magnesium dependent process (Page 184). The potential associations of serum 25(OH)D with mortality, particularly due to cardiovascular disease and colorectal cancer were found to be modified by magnesium ingestion (Page 185). Magnesium potentiates vitamin D activities, possibly by increasing its absorption and endogenous activation (Page 186). Studies have shown that magnesium supplementation can increase the effectiveness of vitamin D activity (Page 186).
Xv provides an overview of the use of Vitamin K2 in the treatment of cancer. Vitamin K2 (VK2) exerts anticancer effects on a number of cancer cell lines, and is considered to be a prospective novel agent for the treatment of cancer. The combination of VK2 and established chemotherapeutics may achieve better results with fewer side effects (Abstract). Previous reports have demonstrated that VK2 can inhibit several neoplastic cell lines at different levels by inducing apoptosis and cell cycle arrest of cancer cells. Hence VK2 is a potential chemotherapeutic candidate for the treatment of cancer (Introduction). Vitamin D3 is another micronutrient capable of restricting the growth of cancer cells by inhibiting proliferation and stimulating differentiation. However, an adverse effects of vitamin D3 treatment is hypercalcemia, which can lead to vascular calcification. VK2 regulates the calcium deposition between bone tissue and other tissue, and inhibits the formation of vascular calcified foci. The combination of vitamin D3 with VK2 on cancer cells can synergistically improve the reduction of cellular differentiation and also significantly reduces the risk of hypercalcemia and vascular calcification (Synergistic Effect of VK2 in combination with other chemotherapeutics, Page 8931). VK2 can positively inhibit cancer cells, and appears to be an extremely promising agent with limited toxicity with can be a useful option for the clinical therapy of cancer (Page 8932).
Ascertaining the Differences Between the Prior Art and the Claims at Issue:
The prior art does not specifically teach the treatment of non-melanoma skin cancer in a patient in need thereof comprising administering a therapeutically effective amount of vitamin D3, its metabolites, vitamin K, or magnesium.
Resolving the Level of Ordinary Skill in the Pertinent Art:
The artisan would be a medical doctor, with further specialization in dermatology and oncology. This training would include the use of chemotherapeutics and their use at therapeutically effective amounts to result in the treatment of the cancer.
Considering Objective Evidence Present in the Application Indicating Obviousness or Nonobviousness:
Albert, Uhmann, Trump, Uwitonze, and Xv are considered analogous to the claimed invention as all are involved in the use of vitamin D in the treatment of disease. Therefore, it would have been prima facie obvious to one of ordinary skill in the art the time of the effective filing date of the instant application to utilize cholecalciferol, calcidiol, and calcitriol, in combination with vitamin K2 and magnesium, for the treatment of basal cell carcinoma as Albert and Uhmann demonstrate that it is known in the art that each of cholecalciferol, calcidiol, and calcitriol display anti-cancer properties in BCC and act through a known receptor pathway known to inhibit the growth of this cancer. Trump further states that a limiting factor for the use of calcitriol, which is the most potent form of vitamin D, is its low bioavailability. It is known that cholecalciferol and calcidiol are precursors to the active calcitriol, and require metabolism via enzymes. Uwitonze states that these enzymes require magnesium. Thus, it would be obvious to further incorporate magnesium to ensure that the conversion of the pro-drug forms of calcitriol is not limited by enzyme saturation or lack of co-factors. Further, it is known that there is some risk of impact to calcium homeostasis with high doses of calcitriol. Xv establishes that Vitamin K2 is both beneficial for regulating this calcium homeostasis, and states that it may work synergistically with vitamin D in the treatment of cancer. In view of these teachings, it would be prima facie obvious to one of ordinary skill in the art to combine these agents which individually are known to be useful for the treatment of cancer, to form a third composition for the treatment of cancer (See MPEP § 2144.06 I).
Regarding Claim 14, Albert states that each form of vitamin D (cholecalciferol, calcidiol, and calcitriol) are effective at inhibiting Hh signaling, and thus would be effective at treating BCC. Thus, it would be obvious to utilize cholecalciferol on its own for the treatment of BCC as the artisan would recognize that on its own it is effective for inhibiting these pathways, and would also understand that following metabolism, it would be converted into forms which are known to have more potency in inhibiting these pathways.
Regarding Claims 1, 4, 5, 9-10, 12, and 15, it would be obvious to generate a pharmaceutical composition comprising these ingredients in order to improve patient compliance by making dosing easier for the patient, ensuring consistent delivery of each therapeutic. Pharmaceutical formulation is also known in the art to enhance the delivery of the therapeutic, improving properties such as solubility, absorption, and bioavailability.
Conclusion
Claims 1, 4, 5, 9, 10, 12, 14 and 15 are rejected.
THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to PHILLIP MATTHEW RZECZYCKI whose telephone number is (703)756-5326. The examiner can normally be reached Monday Thru Friday 730AM-5PM EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at 571-272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/P.M.R./ Examiner, Art Unit 1625
/JOHN S KENYON/ Primary Patent Examiner, Art Unit 1625